Inhibitors of CSF1R, CCL2 and CCR2, CD47/SIRPα complex antagonists, CD40 agonist antibodies, and inhibitors of PI3Kγ and TREM2 protein are undergoing clinical evaluation for various tumor types [58]. Here, CD40 is linked to neoplasm.